Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
setanaxib + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Calliditas Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Setanaxib + pembrolizumab is an investigational combination therapy for cancer, specifically evaluated in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Setanaxib is a selective inhibitor of NADPH oxidase isoforms NOX1 and NOX4, which reduces oxidative stress and modulates fibroblast activity in the tumor microenvironment, showing antifibrotic and immunomodulatory effects. Pembrolizumab is a monoclonal antibody and immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor to restore antitumor immune responses. This combination leverages dual mechanisms: direct modulation of the tumor microenvironment and enhancement of antitumor immunity. Both drugs are administered together: setanaxib orally and pembrolizumab intravenously[1][3][5][7].
- Other names
- setanaxib + KEYTRUDA
02
Targets
NOX1 (NADPH oxidase 1)PDCD1 (Programmed cell death protein 1 receptor)NOX4 (NADPH oxidase 4)
Beyond the preview
Go deeper on setanaxib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on setanaxib + pembrolizumab.